Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Eli Lilly Scoops Up Scorpion Therapeutics' Early-Stage Cancer Program For $2.5 Billion
Eli Lilly plans to acquire Scorpion's PI3Kα program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its ...
Should You Buy the Dip in Eli Lilly Stock Right Now?
All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...
Lilly to pay $2.5B for Boston biotech's lead cancer drug
Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...
Nasdaq4d
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?
The latest declines in Eli Lilly's stock price occurred in response to management's presentation ... On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation ...
Business Insider10d
Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B
The company states: “Eli Lilly (LLY) and Scorpion Therapeutics announced a ... The new company will be led by Dr. Friedman and members of the current Scorpion management team and will focus on ...
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?
In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On Jan. 14, CEO David Ricks told investors that 2024 sales would come in at ...